Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy

Objective: To assess the safety and efficacy of edoxaban for the treatment of venous thromboembolism (VTE) secondary to active malignancy. Materials and Methods: We enrolled 48 patients with newly diagnosed VTE secondary to active malignancy that was treated with oral edoxaban for 1 year between Sep...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Nobuhiro, Miyamoto, Takamichi, Iwai, Takamasa, Yamaguchi, Junji, Hijikata, Sadahiro, Watanabe, Keita, Sagawa, Yuichiro, Masuda, Ryo, Miyazaki, Ryoichi, Miwa, Naoyuki, Sekigawa, Masahiro, Yamaguchi, Tetsuo, Nagata, Yasutoshi, Nozato, Toshihiro, Obayashi, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese College of Angiology / The Japanese Society for Vascular Surgery / Japanese Society of Phlebology 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835434/
https://www.ncbi.nlm.nih.gov/pubmed/29515704
http://dx.doi.org/10.3400/avd.oa.17-00054
_version_ 1783303811704553472
author Hara, Nobuhiro
Miyamoto, Takamichi
Iwai, Takamasa
Yamaguchi, Junji
Hijikata, Sadahiro
Watanabe, Keita
Sagawa, Yuichiro
Masuda, Ryo
Miyazaki, Ryoichi
Miwa, Naoyuki
Sekigawa, Masahiro
Yamaguchi, Tetsuo
Nagata, Yasutoshi
Nozato, Toshihiro
Obayashi, Toru
author_facet Hara, Nobuhiro
Miyamoto, Takamichi
Iwai, Takamasa
Yamaguchi, Junji
Hijikata, Sadahiro
Watanabe, Keita
Sagawa, Yuichiro
Masuda, Ryo
Miyazaki, Ryoichi
Miwa, Naoyuki
Sekigawa, Masahiro
Yamaguchi, Tetsuo
Nagata, Yasutoshi
Nozato, Toshihiro
Obayashi, Toru
author_sort Hara, Nobuhiro
collection PubMed
description Objective: To assess the safety and efficacy of edoxaban for the treatment of venous thromboembolism (VTE) secondary to active malignancy. Materials and Methods: We enrolled 48 patients with newly diagnosed VTE secondary to active malignancy that was treated with oral edoxaban for 1 year between September 2014 and August 2015. We retrospectively examined the presence or absence of recurrent symptomatic VTE, VTE-related mortality, and bleeding events. Results: No recurrent symptomatic VTE or VTE-related deaths were recorded, enabling efficient assessment. Treatment safety was determined based on the reports of bleeding. Bleeding was reported in two patients, with serious bleeding in one of them. Conclusion: Edoxaban is safe and effective for the treatment of VTE secondary to active malignancy.
format Online
Article
Text
id pubmed-5835434
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Japanese College of Angiology / The Japanese Society for Vascular Surgery / Japanese Society of Phlebology
record_format MEDLINE/PubMed
spelling pubmed-58354342018-03-07 Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy Hara, Nobuhiro Miyamoto, Takamichi Iwai, Takamasa Yamaguchi, Junji Hijikata, Sadahiro Watanabe, Keita Sagawa, Yuichiro Masuda, Ryo Miyazaki, Ryoichi Miwa, Naoyuki Sekigawa, Masahiro Yamaguchi, Tetsuo Nagata, Yasutoshi Nozato, Toshihiro Obayashi, Toru Ann Vasc Dis Original Article Objective: To assess the safety and efficacy of edoxaban for the treatment of venous thromboembolism (VTE) secondary to active malignancy. Materials and Methods: We enrolled 48 patients with newly diagnosed VTE secondary to active malignancy that was treated with oral edoxaban for 1 year between September 2014 and August 2015. We retrospectively examined the presence or absence of recurrent symptomatic VTE, VTE-related mortality, and bleeding events. Results: No recurrent symptomatic VTE or VTE-related deaths were recorded, enabling efficient assessment. Treatment safety was determined based on the reports of bleeding. Bleeding was reported in two patients, with serious bleeding in one of them. Conclusion: Edoxaban is safe and effective for the treatment of VTE secondary to active malignancy. Japanese College of Angiology / The Japanese Society for Vascular Surgery / Japanese Society of Phlebology 2017-12-25 /pmc/articles/PMC5835434/ /pubmed/29515704 http://dx.doi.org/10.3400/avd.oa.17-00054 Text en Copyright © 2017 Annals of Vascular Diseases http://creativecommons.org/licenses/by-nc-sa/4.0/ This article is distributed under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided the credit of the original work, a link to the license, and indication of any change are properly given, and the original work is not used for commercial purposes. Remixed or transformed contributions must be distributed under the same license as the original.
spellingShingle Original Article
Hara, Nobuhiro
Miyamoto, Takamichi
Iwai, Takamasa
Yamaguchi, Junji
Hijikata, Sadahiro
Watanabe, Keita
Sagawa, Yuichiro
Masuda, Ryo
Miyazaki, Ryoichi
Miwa, Naoyuki
Sekigawa, Masahiro
Yamaguchi, Tetsuo
Nagata, Yasutoshi
Nozato, Toshihiro
Obayashi, Toru
Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
title Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
title_full Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
title_fullStr Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
title_full_unstemmed Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
title_short Assessment of the Safety and Efficacy of Edoxaban for the Treatment of Venous Thromboembolism Secondary to Active Malignancy
title_sort assessment of the safety and efficacy of edoxaban for the treatment of venous thromboembolism secondary to active malignancy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835434/
https://www.ncbi.nlm.nih.gov/pubmed/29515704
http://dx.doi.org/10.3400/avd.oa.17-00054
work_keys_str_mv AT haranobuhiro assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT miyamototakamichi assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT iwaitakamasa assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT yamaguchijunji assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT hijikatasadahiro assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT watanabekeita assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT sagawayuichiro assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT masudaryo assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT miyazakiryoichi assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT miwanaoyuki assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT sekigawamasahiro assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT yamaguchitetsuo assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT nagatayasutoshi assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT nozatotoshihiro assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy
AT obayashitoru assessmentofthesafetyandefficacyofedoxabanforthetreatmentofvenousthromboembolismsecondarytoactivemalignancy

Ejemplares similares